What is Adalimumab?

Category: Prescription Drugs

Most popular types: Humira Humira Pen Humira Pen Psoriasis Starter Package Show all

false

Adalimumab is an injectable product that can be used to treat a variety of autoimmune conditions including: rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis.

Reported purpose & perceived effectiveness
Purpose Patients Evaluations Perceived Effectiveness
Rheumatoid arthritis 295 168
Crohn's disease 202 97
Psoriasis 111 51
Ankylosing spondylitis 75 35
Psoriatic arthritis 72 52
Ulcerative colitis 26 21

Show all 50 reasons taken


  • Major
  • Moderate
  • Slight
  • None
  • Can't tell

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations
Severe
52
Moderate
73
Mild
99
None
162

Commonly reported side effects and conditions associated with Adalimumab

Side effect Patients
Fatigue 16
Immune system weak 15
Headaches 14
Nausea 14
Injection site pain 8
Injection site reaction 8

Show all 177 reported side effects

Dosages

Based on patients currently taking Adalimumab

Dosage Patients
40 mg/0.8 mL every other week 21
50 mg every other week 17
1 mixed every other week 13
100 mg every other week 13
40 mg every other week 9
40 mg/0.8 mL weekly 8
40 mg weekly 3
20 mg/0.4 mL every other week 2
50 mg weekly 2
100 mg weekly 2

See all 23 dosages

Why patients stopped taking Adalimumab

Multiple reasons could be selected

Reason Patients
Did not seem to work 167
Side effects too severe 90
Doctor's advice 76
Other 36
Expense 14
Change in health plan coverage 11
Personal research 8
Course of treatment ended 7
See all 281 patients who've stopped taking Adalimumab

Duration

Currently taking Adalimumab

Duration Patients
Less than 1 month 1
1 - 6 months 11
6 months - 1 year 8
1 - 2 years 22
2 - 5 years 36
5 - 10 years 21
10 years or more 5

Stopped taking Adalimumab

Duration Patients
Less than 1 month 49
1 - 6 months 70
6 months - 1 year 66
1 - 2 years 39
2 - 5 years 43
5 - 10 years 10
10 years or more 5
Adherence
Adherence Evaluations
Always 320
Usually 41
Sometimes 8
Never taken as prescribed 17
Burden
Burden Evaluations
Very hard to take 33
Somewhat hard to take 80
A little hard to take 103
Not at all hard to take 170
Cost per month
Cost per month Evaluations
$200+ 30
$100-199 2
$50-99 15
$25-49 22
< $25 179
Not specified 138

What people switch to and from

Patients started taking Adalimumab after stopping:

Treatment Patients
Etanercept (Enbrel SureClick) 41
Infliximab (Remicade) 41
Methotrexate (Apo-Methotrexate) 26
Hydroxychloroquine (Plaquenil) 8
Mesalamine (Pentasa) 8

Show all 34 treatments patients report switching from

Patients stopped taking Adalimumab and switched to:

Treatment Patients
Etanercept (Enbrel SureClick) 22
Infliximab (Remicade) 17
Abatacept (Orencia) 11
Certolizumab (Cimzia) 11
Vedolizumab (Entyvio) 8

Show all 21 treatments patients report switching to

Last updated:

17 patient evaluations for Adalimumab

Aug 25, 2017 (Started Aug 20, 2014)

  • Effectiveness
    Moderate (for rheumatoid arthritis)
  • Side effects
    Moderate (restless feeling in legs)
  • Adherence
    Always
  • Burden
    Not at all hard to take
Dosage: 50 mg Every Other Week

  • 0 helpful marks

Aug 21, 2016 (Started Jul 01, 2007)

  • Effectiveness
    None (for rheumatoid arthritis)
  • Side effects
    None
  • Adherence
    Always
  • Burden
    A little hard to take
Cost: < $25 monthly

Jun 30, 2008 (Started Jul 01, 2007)

  • Effectiveness
    None (for rheumatoid arthritis)
  • Side effects
    None
  • Adherence
    Always
  • Burden
    A little hard to take
Dosage: 50 mg Weekly
Cost: < $25 monthly

  • 0 helpful marks

Jun 15, 2016 (Started Jul 01, 2014)

  • Effectiveness
    Moderate (for ankylosing spondylitis)
  • Side effects
    None
  • Adherence
    Always
  • Burden
    A little hard to take
Dosage: 50 mg Every Other Week
Cost: $25-49 monthly

  • 1 helpful mark
Last updated:
Showing 3 of 17 patient evaluations for Adalimumab